109 related articles for article (PubMed ID: 15885460)
1. Pharmacokinetics of DA-8159, a new erectogenic, administered at 10:00 h versus 22:00 h in rats.
Lee JH; Kim YC; Kwon JW; Kim WB; Lee MG
Int J Pharm; 2005 May; 296(1-2):94-102. PubMed ID: 15885460
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate.
Shim HJ; Kim YC; Kim EJ; Kim DG; Kwon JW; Kim WB; Lee MG
Biopharm Drug Dispos; 2004 Apr; 25(3):137-42. PubMed ID: 15083502
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of intravenous and oral DA-8159, a new erectogenic, in rats with protein-calorie malnutrition.
Shim HJ; Kim YC; Lee JH; Ahn BO; Kwon JW; Kim WB; Lee I; Lee MG
J Pharm Pharmacol; 2004 Dec; 56(12):1543-50. PubMed ID: 15563761
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats.
Lee SJ; Bae SK; Kwon JW; You M; Lee DC; Lee MG
J Pharm Pharmacol; 2005 Nov; 57(11):1397-405. PubMed ID: 16259771
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats.
Kim YC; Shim HJ; Lee JH; Kim DS; Kwon JW; Kim WB; Lee I; Lee MG
Biopharm Drug Dispos; 2005 Oct; 26(7):309-20. PubMed ID: 16035131
[TBL] [Abstract][Full Text] [Related]
6. Subacute toxicities and toxicokinetics of DA-8159, a new phosphodiesterase type V inhibitor, after single and 4-week repeated oral administration in rats.
Shim HJ; Kim YC; Jang JM; Park KJ; Kim DH; Kang KK; Ahn BO; Kwon JW; Kim WB; Lee MG
Biopharm Drug Dispos; 2003 Dec; 24(9):409-18. PubMed ID: 14689469
[TBL] [Abstract][Full Text] [Related]
7. Species differences in the formation of DA-8164 after intravenous and/or oral administration of DA-8159, a new erectogenic, to mice, rats, rabbits, dogs and humans.
Shim HJ; Kim YC; Lee JH; Park KJ; Kwon JW; Kim WB; Lee MG
Biopharm Drug Dispos; 2005 May; 26(4):161-6. PubMed ID: 15803515
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects.
Shin HS; Bae SK; Lee MG
Int J Pharm; 2006 Aug; 320(1-2):64-70. PubMed ID: 16730145
[TBL] [Abstract][Full Text] [Related]
9. Effects of bacterial lipopolysaccharide on the pharmacokinetics of DA-8159, a new erectogenic, in rats.
Lee JH; Kim YC; Kwon JW; Kim WB; Lee MG
Res Commun Mol Pathol Pharmacol; 2005; 117-118():179-87. PubMed ID: 18426088
[TBL] [Abstract][Full Text] [Related]
10. Effects of water deprivation for 72 hours on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats.
Bae SK; Kim YC; Lee JK; Kwon JW; Yoo M; Lee I; Lee MG
Biopharm Drug Dispos; 2006 Apr; 27(3):147-56. PubMed ID: 16408258
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
Shim HJ; Kim YC; Park KJ; Kim DS; Kwon JW; Kim WB; Lee MG
J Pharm Sci; 2003 Nov; 92(11):2185-95. PubMed ID: 14603504
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, stability, and blood partition of DA-8159, a new phosphodiesterase V inhibitor.
Shim HJ; Lee EJ; Kim SH; Kim SH; Yoo M; Kwon JW; Kim WB; Lee HS; Lee MG
Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):275-86. PubMed ID: 11913718
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of DA-6034, an agent for inflammatory bowel disease, in rats and dogs: Contribution of intestinal first-pass effect to low bioavailability in rats.
Chung HJ; Choi YH; Choi HD; Jang JM; Shim HJ; Yoo M; Kwon JW; Lee MG
Eur J Pharm Sci; 2006 Mar; 27(4):363-74. PubMed ID: 16387482
[TBL] [Abstract][Full Text] [Related]
15. Effects of acute renal failure on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats.
Bae SK; Kwon JW; Kim WB; Lee I; Lee MG
Biopharm Drug Dispos; 2006 Jan; 27(1):29-37. PubMed ID: 16302289
[TBL] [Abstract][Full Text] [Related]
16. Effects of protein-calorie malnutrition on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats.
Bae SK; Lee SJ; Kwon JW; Kim WB; Lee MG
J Pharm Pharmacol; 2004 May; 56(5):635-42. PubMed ID: 15142341
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic changes of oltipraz after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine.
Bae SK; Lee SJ; Lee JY; Lee Y; Lee I; Kim SG; Lee MG
Int J Pharm; 2004 May; 275(1-2):227-38. PubMed ID: 15081153
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, blood partition and protein binding of DA-7867, a new oxazolidinone.
Bae SK; Chung WS; Kim EJ; Rhee JK; Kwon JW; Kim WB; Lee MG
Biopharm Drug Dispos; 2004 Apr; 25(3):127-35. PubMed ID: 15083501
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin.
Kim YC; Kwon JW; Kim WB; Lee I; Lee MG
J Pharm Sci; 2004 Sep; 93(9):2374-87. PubMed ID: 15295797
[TBL] [Abstract][Full Text] [Related]
20. Gender differences in the pharmacokinetics of DA-6034, a derivative of flavonoids, in rats.
Yang SH; Bae SK; Kwon JW; Yoo M; Lee MG
Biopharm Drug Dispos; 2006 Jan; 27(1):47-51. PubMed ID: 16302288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
